MARKET

BBIO

BBIO

Bridgebio Pharma
NASDAQ
66.48
-1.13
-1.67%
After Hours: 66.55 +0.07 +0.11% 16:48 02/27 EST
OPEN
66.42
PREV CLOSE
67.61
HIGH
68.47
LOW
65.46
VOLUME
2.26M
TURNOVER
--
52 WEEK HIGH
84.94
52 WEEK LOW
28.33
MARKET CAP
12.89B
P/E (TTM)
-17.5641
1D
5D
1M
3M
1Y
5Y
1D
BridgeBio Pharma Chief Accounting Officer Maricel Apuli Disposes of Common Shares
Reuters · 48m ago
What BridgeBio Pharma (BBIO)'s Surging 2025 Revenue and Growing Losses Means For Shareholders
Simply Wall St · 10h ago
Ionis Pharmaceuticals: Digesting Recent Events
Seeking Alpha · 14h ago
BBIO February 2027 Options Begin Trading
NASDAQ · 1d ago
BridgeBio Pharma Earnings Call Signals Profitable Pivot
TipRanks · 1d ago
BridgeBio’s Infigratinib Data Reframes Growth Prospects In Rare Disease Franchise
Simply Wall St · 1d ago
BridgeBio Pharma Price Target Raised to $95.00/Share From $86.00 by Truist Securities
Dow Jones · 2d ago
BridgeBio Pharma Is Maintained at Buy by Truist Securities
Dow Jones · 2d ago
More
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.

Webull offers BridgeBio Pharma Inc stock information, including NASDAQ: BBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BBIO stock methods without spending real money on the virtual paper trading platform.